PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?

ABSTRACT: Prostate-specific membrane antigen (PSMA) is highly expressed on the membrane of most prostate cancer cells and to a lesser extent in normal tissues. Many vectors targeting this protein have been created over the past decade and numerous clinical studies have positively demonstrated the tolerance and efficacy of radiolabeled prostate-specific membrane antigen ligands for PSMA radioligand therapy (PRLT). Preliminary results are encouraging that PRLT will become an important addition to the current therapeutic options in a number of settings. Improvement in radiopharmaceutical targeting and combination with other oncological agents are under investigation to further improve its therapeutic efficacy. These encouraging results have led to the development of other therapies using PSMA as a targ

SUBMITTER: Giraudet AL 

PROVIDER: S-EPMC8554551 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature